APRINOIA THERAPEUTICS
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.
APRINOIA THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Medical Therapeutics
Founded:
2015-05-20
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aprinoia.com
Total Employee:
11+
Status:
Active
Contact:
+1-617-225-4415
Email Addresses:
[email protected]
Total Funding:
61.93 M USD
Technology used in webpage:
Euro HSTS Microsoft DigiCert SSL Microsoft Azure Wix Media GeoTrust SSL Constant Hosting Microsoft Azure Asia East Region
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Applied Immune Technologies
Applied Immune Technologies is focused on developing therapeutic molecules for cancer, viral, and autoimmune diseases.ย
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Prose Biosystems
biotechnology, therapeutics
Regend Therapeutics
Regend Therapeutics focuses on the human organ regenerative medicine business
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Venture Round - APRINOIA Therapeutics
IMM Private Equity
IMM Private Equity investment in Series C - APRINOIA Therapeutics
KTB Network
KTB Network investment in Series C - APRINOIA Therapeutics
Yantai Dongcheng Pharmaceutical
Yantai Dongcheng Pharmaceutical investment in Series C - APRINOIA Therapeutics
KTB Network
KTB Network investment in Series B - APRINOIA Therapeutics
DCI Partners
DCI Partners investment in Series B - APRINOIA Therapeutics
TaiAn Technologies
TaiAn Technologies investment in Series B - APRINOIA Therapeutics
ShangPharma
ShangPharma investment in Series B - APRINOIA Therapeutics
Company K Partners
Company K Partners investment in Series A - APRINOIA Therapeutics
IMM Investment
IMM Investment investment in Series A - APRINOIA Therapeutics
Official Site Inspections
http://www.aprinoia.com Semrush global rank: 5.61 M Semrush visits lastest month: 1.29 K
- Host name: apache2-twiddle.iad1-shared-b7-38.dreamhost.com
- IP address: 67.205.26.10
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "APRINOIA Therapeutics"
About Us | APRINOIA Therapeutics
Our name, APRINOIA, merges the Latin word for sunlight, โapricum,โ with the Greek suffix for the mind, โnoia.โ Our name reflects our missionโto shed light on ways to better diagnose and treat these dreaded neurodegenerative disorders โฆSee details»
Home | APRINOIA Therapeutics
At APRINOIA, we bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, ฮฑ-synuclein, and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as โฆSee details»
APRINOIA Therapeutics - Crunchbase Company Profile โฆ
Organization. APRINOIA Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. โฆSee details»
Aprinoia Therapeutics 2025 Company Profile: โฆ
Aprinoia Therapeutics General Information Description. Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' โฆSee details»
APRINOIA Therapeutics - Contacts, Employees, Board Members
Organization. APRINOIA Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of โฆSee details»
APRINOIA Therapeutics - IPOScoop
To support Aprinoiaโs investigator-initiated programs and our programs, we have established relationships with contract manufacturing organization (โCMOsโ) at 20 sites across Asia, โฆSee details»
APRINOIA Therapeutics Inc. - VentureRadar
APRINOIA Therapeutics Inc. with operations in Hong Kong, Taipei, Tokyo, Suzhou, Shanghai, and Boston, was founded in May 2015. APRINOIA is a drug discovery and development โฆSee details»
APRINOIA Therapeutics โ A clearer picture, a brighter โฆ
At APRINOIA, we bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, ฮฑ-synuclein, and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as โฆSee details»
APRINOIA Therapeutics - Craft
APRINOIA Therapeutics is a late-stage biotechnology company developing diagnostic tools and novel therapies for patients with neurodegenerative diseases. It offers diagnostic and โฆSee details»
APRINOIA Therapeutics Announces Strategic Investment From
Sep 11, 2023 APRINOIA Therapeutics Inc., is a global clinical-stage biopharmaceutical company, headquartered in Cambridge, MA, developing novel therapeutics and precision โฆSee details»
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce โฆ
Palm Beach, FL and CAMBRIDGE, MA, January 18, 2023 โ APRINOIA Therapeutics Inc. (โAPRINOIAโ), a clinical-stage biotechnology company focused on neurodegenerative โฆSee details»
Aprinoia Therapeutics - Overview, News & Similar companies
Aug 28, 2023 APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces โฆSee details»
APRINOIA Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
APRINOIA
Aprinoia Therapeutics Clinical Archiving System. Username. Password. Log In. meSubmit u Cancel. Forgot Password? Version: 2.0.47 ...See details»
APRINOIA Therapeutics Inc | Alzheimer's Drug Discovery Foundation
Jul 1, 2023 APRINOIA Therapeutics Inc. Lili Zhang, Ph.D. | Massachusetts, United States ... View all funding to this organization (2) View all funding to this investigator (2) GET IN โฆSee details»
News | APRINOIA Therapeutics
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy Fast Track Designation follows โฆSee details»
OpenAI Says Company to Remain Under Nonprofit Control - WSJ
4 days ago Maker of ChatGPT to remain under the control of a nonprofit organization. By . Keach Hagey. Share. Resize. Listen (2 min) When Sam Altman co-founded OpenAI in 2015, โฆSee details»
APRINOIA Therapeutics Inc | Alzheimer's Drug Discovery Foundation
Jul 1, 2023 To address this significant unmet need, Aprinoia is developing 18 F-APN-1607 (APN-1607), a new generation PET tracer, that will enable clinicians to visualize tau, an โฆSee details»
OpenAI reverses course, says its nonprofit will remain in control of ...
5 days ago OpenAI has decided that its nonprofit division will retain control over its for-profit org, after the company initially announced that it planned to convert to a for-profit organization.See details»
Our Science | APRINOIA Therapeutics
APRINOIA provides first-in-class solutions in noninvasive precision diagnostics for neurodegenerative diseases. Our positron emission tomography (PET) tracers target โฆSee details»